{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:17:46Z","timestamp":1787026666996,"version":"build-2736575974"},"reference-count":95,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cardiac sarcoidosis (CS) represents one of the most severe and prognostically unfavorable manifestations of systemic sarcoidosis. Its diagnosis is often delayed due to non-specific symptoms and the patchy myocardial distribution of granulomatous inflammation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To summarize the current understanding of epidemiology, diagnostic strategies, immunopathology, and therapeutic advances in CS, and to propose recommendations for future research and clinical management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods\/scope<\/jats:title>\n                    <jats:p>We analyze epidemiological data, autopsy series, and clinical cohorts to estimate the true prevalence and spectrum of CS. We review diagnostic algorithms combining electrocardiographic, echocardiographic, cardiac MRI, and 18F-FDG PET imaging with histopathological methods. Immunopathological mechanisms are discussed, with particular focus on Th17.1 cells, M2 macrophage polarization, and inflammasome activation. Therapeutic modalities \u2013 including corticosteroids, immunosuppressants, biologics (e.g., TNF inhibitors, IL-1\/IL-18 blockers), and mechanical support (LVAD, transplantation) \u2013 are critically appraised based on existing clinical and registry evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Morphological evidence suggests cardiac involvement in 20%\u201330% of sarcoidosis cases, yet clinically manifest CS is diagnosed in only \u223c5%. Advanced imaging has increased detection of subclinical disease. Th17.1 cells and M2 macrophages appear central in granuloma formation and fibrotic progression, while activation of the NLRP3 inflammasome represents a promising therapeutic target. Corticosteroids remain the first-line therapy; steroid-sparing immunosuppression and biological therapies are under investigation. Heart transplantation yields favorable long-term outcomes in CS, with low rates of rejection and recurrence when accompanied by appropriate surveillance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A multifaceted diagnostic and therapeutic approach is essential for CS. Prospective trials are urgently needed to validate biomarkers, optimize immunomodulatory regimens, and test targeted interventions (e.g., IL-1\/IL-18 blockade, NLRP3 inhibition). In advanced disease, transplantation remains a viable and effective option. Concerted efforts in mechanistic research, biomarker discovery and multicenter clinical trials will be critical to improving prognosis in cardiac sarcoidosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1723644","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T06:43:51Z","timestamp":1773125031000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Cardiac sarcoidosis: from clinical manifestations to heart transplantation"],"prefix":"10.3389","volume":"13","author":[{"given":"Anna","family":"Starshinova","sequence":"first","affiliation":[{"name":"Almazov National Medical Research Centre","place":["Saint Petersburg, Russia"]},{"name":"Laboratory of Probabilistic Methods in Analysis, Faculty of Mathematics and Computer Science, Saint Petersburg State University","place":["Saint Petersburg, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Fedotov","sequence":"additional","affiliation":[{"name":"Laboratory of Probabilistic Methods in Analysis, Faculty of Mathematics and Computer Science, Saint Petersburg State University","place":["Saint Petersburg, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Musaeva","family":"Bulgun","sequence":"additional","affiliation":[{"name":"Almazov National Medical Research Centre","place":["Saint Petersburg, Russia"]},{"name":"Laboratory of Probabilistic Methods in Analysis, Faculty of Mathematics and Computer Science, Saint Petersburg State University","place":["Saint Petersburg, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Kudryavtsev","sequence":"additional","affiliation":[{"name":"Almazov National Medical Research Centre","place":["Saint Petersburg, Russia"]},{"name":"Institute of Experimental Medicine","place":["Saint Petersburg, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artem","family":"Rubinstein","sequence":"additional","affiliation":[{"name":"Almazov National Medical Research Centre","place":["Saint Petersburg, Russia"]},{"name":"Institute of Experimental Medicine","place":["Saint Petersburg, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur D.","family":"Aquino","sequence":"additional","affiliation":[{"name":"Almazov National Medical Research Centre","place":["Saint Petersburg, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry","family":"Kudlay","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Institute of Pharmacy, I.M. Sechenov First Moscow State Medical University","place":["Moscow, Russia"]},{"name":"Institute of Immunology FMBA of Russia","place":["Moscow, Russia"]},{"name":"Department of Pharmacognosy and Industrial Pharmacy, Faculty of Fundamental Medicine, Lomonosov Moscow State University","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeny","family":"Shlyakhto","sequence":"additional","affiliation":[{"name":"Almazov National Medical Research Centre","place":["Saint Petersburg, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.3390\/life13041047","article-title":"Sarcoidosis and autoimmune inflammatory syndrome induced by adjuvants.","volume":"13","author":"Starshinova","year":"2023","journal-title":"Life."},{"key":"B2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12929-019-0537-6","article-title":"Host-microbe interactions in the pathogenesis and clinical course of sarcoidosis.","volume":"26","author":"Inaoka","year":"2019","journal-title":"J Biomed Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1700991","DOI":"10.1183\/13993003.00991-2017","article-title":"Phenotypes of organ involvement in sarcoidosis.","volume":"51","author":"Schupp","year":"2018","journal-title":"Eur Respir J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3390\/pathophysiology28040035","article-title":"Small fiber neuropathy in sarcoidosis.","volume":"28","author":"Gavrilova","year":"2021","journal-title":"Pathophysiology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1164\/rccm.202002-0251ST","article-title":"Diagnosis and detection of sarcoidosis. An official American thoracic society clinical practice guideline.","volume":"201","author":"Crouser","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41572-019-0096-x","article-title":"Sarcoidosis.","volume":"5","author":"Grunewald","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B7","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s11886-019-1238-1","article-title":"Cardiac sarcoidosis.","volume":"21","author":"Mankad","year":"2019","journal-title":"Curr Cardiol Rep"},{"key":"B8","doi-asserted-by":"publisher","first-page":"5897","DOI":"10.15829\/1560-4071-2024-5897","article-title":"Isolated cardiac sarcoidosis: a case report.","volume":"29","author":"Skomkina","year":"2024","journal-title":"Russian J Cardiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s12016-014-8450-y","article-title":"The clinical features of sarcoidosis: a comprehensive review.","volume":"49","author":"Judson","year":"2015","journal-title":"Clin Rev Allergy Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1161\/01.cir.58.6.1204","article-title":"Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis.","volume":"58","author":"Silverman","year":"1978","journal-title":"Circulation"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.hrthm.2014.03.043","article-title":"HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis.","volume":"11","author":"Birnie","year":"2014","journal-title":"Heart Rhythm"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e005001","DOI":"10.1161\/CIRCIMAGING.116.005001","article-title":"Presence of late gadolinium enhancement by cardiac magnetic resonance among patients with suspected Cardiac sarcoidosis is associated with adverse cardiovascular prognosis: a systematic review and meta-analysis.","volume":"9","author":"Hulten","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"B13","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.jcmg.2017.04.020","article-title":"Prognostic impact of extent, severity, and heterogeneity of abnormalities on 18F-FDG PET scans for suspected Cardiac sarcoidosis.","volume":"11","author":"Sperry","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"B14","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S0735-1097(03)00332-2","article-title":"Identification of cardiac sarcoidosis with 13N-ammonia and 18F-FDG PET.","volume":"42","author":"Yamagishi","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/j.1365-2796.2011.02396.x","article-title":"Diagnosing isolated cardiac sarcoidosis: a challenge evaluated by cardiac magnetic resonance, PET, and endomyocardial biopsy.","volume":"4","author":"Kandolin","year":"2011","journal-title":"Circ Heart Fail"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.3390\/jcm13113275","article-title":"Are endomyocardial ventricular biopsies useful for assessing myocardial fibrosis?","volume":"13","author":"Makarov","year":"2024","journal-title":"J Clin Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2004079","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis.","volume":"58","author":"Baughman","year":"2021","journal-title":"Eur Respir J"},{"key":"B18","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1183\/2312508X.erm9622","article-title":"Sarcoidosis. European respiratory society monograph.","volume":"96","author":"Rossides","year":"2022","journal-title":"J. Internal Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"6974","DOI":"10.3390\/jcm13226974","article-title":"Chronic sarcoidosis: diagnostic difficulties and search for new criteria of inflammatory activity (a case report and literature review).","volume":"13","author":"Starshinova","year":"2024","journal-title":"J Clin Med"},{"key":"B20","first-page":"2153","article-title":"Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations.","volume":"119","author":"Perry","year":"2007","journal-title":"Arch Pathol Lab Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1161\/CIRCULATIONAHA.109.851352","article-title":"Detection of myocardial damage in patients with sarcoidosis.","volume":"120","author":"Patel","year":"2009","journal-title":"Circulation"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e1197","DOI":"10.1161\/CIR.0000000000001240","article-title":"Diagnosis and management of Cardiac sarcoidosis: a scientific statement from the American Heart Association.","volume":"149","author":"Cheng","year":"2024","journal-title":"Circulation"},{"key":"B23","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jacc.2016.03.605","article-title":"Cardiac sarcoidosis.","volume":"68","author":"Birnie","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/s11897-024-00683-9","article-title":"Emerging biomarkers in Cardiac sarcoidosis and other inflammatory cardiomyopathies.","volume":"21","author":"Roumi","year":"2024","journal-title":"Curr Heart Fail Rep"},{"key":"B25","first-page":"3640","article-title":"Propionibacterium acnes as a possible pathogen of sarcoidosis.","volume":"37","author":"Ishige","year":"1999","journal-title":"J Clin Microbiol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1056\/NEJMra071714","article-title":"Sarcoidosis.","volume":"357","author":"Iannuzzi","year":"2007","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1136\/hrt.2005.080481","article-title":"Cardiac sarcoidosis.","volume":"92","author":"Doughan","year":"2006","journal-title":"Heart"},{"key":"B28","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3978\/j.issn.2223-3652.2015.12.13","article-title":"Cardiac sarcoidosis-state of the art review.","volume":"6","author":"Hulten","year":"2016","journal-title":"Cardiovasc Diagn Ther"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1164\/rccm.201507-1499OC","article-title":"IFN-\u03b3-producing T-helper 17.1 cells are increased in sarcoidosis and are more prevalent than T-helper type 1 cells.","volume":"193","author":"Ramstein","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/rheumatology\/ker316","article-title":"Increased IL-17A expression in granulomas and in circulating memory T cells in sarcoidosis.","volume":"51","author":"Ten Berge","year":"2012","journal-title":"Rheumatology."},{"key":"B31","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.immuni.2023.01.014","article-title":"Single-cell and spatial transcriptomics reveal aberrant lymphoid developmental programs driving granuloma formation.","volume":"56","author":"Krausgruber","year":"2023","journal-title":"Immunity"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1701124","DOI":"10.1183\/13993003.01124-2017","article-title":"Increased T-helper 17.1 cells in sarcoidosis mediastinal lymph nodes.","volume":"51","author":"Broos","year":"2018","journal-title":"Eur Respir J"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1227818","DOI":"10.3389\/fcvm.2023.1227818","article-title":"Integrative single-cell analysis of cardiac and pulmonary sarcoidosis using publicly available cardiac and bronchoalveolar lavage fluid sequencing datasets.","volume":"10","author":"Daoud","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1165\/rcmb.2018-0053OC","article-title":"IL-13-regulated macrophage polarization during granuloma formation in an in vitro human sarcoidosis model.","volume":"60","author":"Locke","year":"2019","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.humimm.2017.10.009","article-title":"Evidence for M2 macrophages in granulomas from pulmonary sarcoidosis: a new aspect of macrophage heterogeneity.","volume":"79","author":"Shamaei","year":"2018","journal-title":"Hum Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1100\/2011\/213962","article-title":"Macrophage polarization in health and disease.","volume":"11","author":"Cassetta","year":"2011","journal-title":"ScientificWorldJournal"},{"key":"B37","doi-asserted-by":"publisher","first-page":"788502","DOI":"10.3389\/fimmu.2021.788502","article-title":"The role of diverse immune cells in sarcoidosis.","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e16206","DOI":"10.1016\/j.heliyon.2023.e16206","article-title":"M2 macrophage polarization in systemic sclerosis fibrosis: pathogenic mechanisms and therapeutic effects.","volume":"9","author":"Hu","year":"2023","journal-title":"Heliyon"},{"key":"B39","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.clim.2010.06.017","article-title":"Alternatively activated alveolar macrophages in pulmonary fibrosis-mediator production and intracellular signal transduction.","volume":"137","author":"Pechkovsky","year":"2010","journal-title":"Clin Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.ajpath.2010.11.065","article-title":"M2 polarized macrophages and giant cells contribute to myofibrosis in neuromuscular sarcoidosis.","volume":"178","author":"Prokop","year":"2011","journal-title":"Am J Pathol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"37","DOI":"10.31083\/j.rcm2502037","article-title":"Cardiac sarcoidosis: a comprehensive clinical review.","volume":"25","author":"Vereckei","year":"2024","journal-title":"Rev Cardiovasc Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"301","DOI":"10.31083\/j.fbl2908301","article-title":"CXCR3-expressing T cells in infections and autoimmunity.","volume":"29","author":"Rubinstein","year":"2024","journal-title":"Front Biosci."},{"key":"B43","doi-asserted-by":"crossref","first-page":"9834133","DOI":"10.4049\/jimmunol.161.11.6413","article-title":"Involvement of the IP-10 chemokine in sarcoid granulomatous reactions.","volume":"161","author":"Agostini","year":"1998","journal-title":"J Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"105822","DOI":"10.1016\/j.rmed.2019.105822","article-title":"CXCL9 and CXCL10 are differentially associated with systemic organ involvement and pulmonary disease severity in sarcoidosis.","volume":"161","author":"Arger","year":"2020","journal-title":"Respir Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.rmed.2019.04.005","article-title":"Serum CXCL11 correlates with pulmonary outcomes and disease burden in sarcoidosis.","volume":"152","author":"Arger","year":"2019","journal-title":"Respir Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"395","DOI":"10.20452\/pamw.2349","article-title":"Chemokine receptor CXCR3 ligands in bronchoalveolar lavage fluid: associations with radiological pattern, clinical course, and prognosis in sarcoidosis.","volume":"124","author":"Piotrowski","year":"2014","journal-title":"Pol Arch Med Wewn"},{"key":"B47","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1378\/chest.124.1.186","article-title":"Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis: a clinical evaluation.","volume":"124","author":"Grutters","year":"2003","journal-title":"Chest"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1301991","DOI":"10.3389\/fimmu.2023.1301991","article-title":"FOXP3+ regulatory T cells are associated with the severity and prognosis of sarcoidosis.","volume":"14","author":"Patterson","year":"2023","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e0223897","DOI":"10.1371\/journal.pone.0223897","article-title":"Sensitivity and specificity of serum soluble interleukin-2 receptor for diagnosing sarcoidosis in a population of patients suspected of sarcoidosis.","volume":"14","author":"Eurelings","year":"2019","journal-title":"PLoS One"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e2023005","DOI":"10.36141\/svdld.v40i1.13499","article-title":"Role of serum soluble interleukin-2 receptor level in the diagnosis of sarcoidosis: a systematic review and meta-analysis.","volume":"40","author":"Gupta","year":"2023","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"B51","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1080\/17476348.2020.1751614","article-title":"Value of serum soluble interleukin-2 receptor as a diagnostic and predictive biomarker in sarcoidosis.","volume":"14","author":"Schimmelpennink","year":"2020","journal-title":"Expert Rev Respir Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"106115","DOI":"10.1016\/j.rmed.2020.106115","article-title":"sIL-2R levels predict the spontaneous remission in sarcoidosis.","volume":"171","author":"Zhou","year":"2020","journal-title":"Respir Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s12931-023-02524-0","article-title":"SACE and IL-2R as serum biomarkers for evaluation of multi-organ involvement and prognosis of sarcoidosis.","volume":"24","author":"Zhou","year":"2023","journal-title":"Respir Res"},{"key":"B54","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1536\/ihj.17-695","article-title":"A multiple biomarker approach in patients with Cardiac sarcoidosis.","volume":"59","author":"Kiko","year":"2018","journal-title":"Int Heart J"},{"key":"B55","doi-asserted-by":"publisher","first-page":"5282","DOI":"10.1002\/ehf2.13614","article-title":"Association of high serum soluble interleukin 2 receptor levels with risk of adverse events in cardiac sarcoidosis.","volume":"8","author":"Kobayashi","year":"2021","journal-title":"ESC Heart Fail"},{"key":"B56","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.cca.2009.09.034","article-title":"Plasma chitotriosidase and CCL18 as surrogate markers for granulomatous macrophages in sarcoidosis.","volume":"411","author":"Boot","year":"2010","journal-title":"Clin Chim Acta"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.rmed.2013.06.004","article-title":"CCL18 in serum, BAL fluid and alveolar macrophage culture supernatant in interstitial lung diseases.","volume":"107","author":"Cai","year":"2013","journal-title":"Respir Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1164\/rccm.200509-1518OC","article-title":"A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18.","volume":"173","author":"Prasse","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1007\/s10067-018-4183-2","article-title":"Significant elevation of the levels of B-cell activating factor (BAFF) in patients with sarcoidosis.","volume":"37","author":"Ando","year":"2018","journal-title":"Clin Rheumatol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1093\/rheumatology\/ket186","article-title":"Elevated serum BAFF levels in patients with sarcoidosis: association with disease activity.","volume":"52","author":"Ueda-Hayakawa","year":"2013","journal-title":"Rheumatology"},{"key":"B61","doi-asserted-by":"publisher","first-page":"72","DOI":"10.46497\/ArchRheumatol.2021.8013","article-title":"Serum B cell activating factor (BAFF) and sarcoidosis activity.","volume":"36","author":"Hashemzadeh","year":"2020","journal-title":"Arch Rheumatol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"e355","DOI":"10.1016\/S2665-9913(24)00338-2","article-title":"Evolution and trajectory of B-cell targeted therapies in rheumatic diseases.","volume":"7","author":"Carter","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"e025803","DOI":"10.1161\/JAHA.122.025803","article-title":"The prognostic value of B-type natriuretic peptide in patients with Cardiac sarcoidosis without heart failure: insights from ILLUMINATE-CS.","volume":"11","author":"Miyakuni","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"B64","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.ijcard.2015.04.144","article-title":"Urinary 8-hydroxy-2\u2019-deoxyguanosine as a novel biomarker of inflammatory activity in patients with cardiac sarcoidosis.","volume":"190","author":"Kobayashi","year":"2015","journal-title":"Int J Cardiol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ijcard.2016.03.003","article-title":"An oxidative stress biomarker, urinary 8-hydroxy-2\u2019-deoxyguanosine, predicts cardiovascular-related death after steroid therapy for patients with active cardiac sarcoidosis.","volume":"212","author":"Myoren","year":"2016","journal-title":"Int J Cardiol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.1093\/eurheartj\/ehac221","article-title":"Long-term outcomes of japanese patients with Cardiac sarcoidosis from the ILLUMINATE-CS registry.","volume":"43","author":"Kusano","year":"2022","journal-title":"Eur Heart J."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/s0002-9149(01)01978-6","article-title":"Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone.","volume":"88","author":"Yazaki","year":"2001","journal-title":"Am J Cardiol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"84","DOI":"10.58838\/2075-1230-2024-102-3-84-94","article-title":"Sarcoidosis phenotyping: analysis of current approaches (review).","volume":"102","author":"Vizel","year":"2024","journal-title":"Tuberculosis Lung Dis."},{"key":"B69","doi-asserted-by":"publisher","first-page":"5986","DOI":"10.15829\/1560-4071-2024-5986","article-title":"Inflammasome - a new look at the therapy of cardiovascular diseases: a review.","volume":"29","author":"Rubinstein","year":"2024","journal-title":"Part I. Russian J Cardiol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1007\/s12350-018-01504-y","article-title":"The prognostic value of quantitating and localizing F-18 FDG uptake in cardiac sarcoidosis.","volume":"27","author":"Flores","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1286684","DOI":"10.3389\/fimmu.2023.1286684","article-title":"Assessment of treatment response in cardiac sarcoidosis based on myocardial 18F-FDG uptake.","volume":"14","author":"Frischknecht","year":"2023","journal-title":"Front Immunol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1900119","DOI":"10.1183\/13993003.00119-2019","article-title":"The NLRP3 inflammasome pathway is activated in sarcoidosis and involved in granuloma formation.","volume":"55","author":"Huppertz","year":"2020","journal-title":"Eur Respir J"},{"key":"B73","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/FJC.0000000000000931","article-title":"Phase 1B, randomized, double-blinded, dose escalation, single-center, repeat dose safety and pharmacodynamics study of the oral NLRP3 inhibitor dapansutrile in subjects with NYHA II-III systolic heart failure.","volume":"77","author":"Wohlford","year":"2020","journal-title":"J Cardiovasc Pharmacol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13024-025-00867-4","article-title":"Biomarkers and therapeutic strategies targeting microglia in neurodegenerative diseases: current status and future directions.","volume":"20","author":"Noh","year":"2025","journal-title":"Mol Neurodegener"},{"key":"B75","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/annrheumdis-2017-212608","article-title":"Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still\u2019s disease.","volume":"77","author":"Gabay","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B76","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1186\/s12967-021-03130-8","article-title":"Interleukin-1 blockade in cardiac sarcoidosis: study design of the multimodality assessment of granulomas in cardiac sarcoidosis: anakinra randomized trial (MAGiC-ART).","volume":"19","author":"Kron","year":"2021","journal-title":"J Transl Med"},{"key":"B77","doi-asserted-by":"publisher","first-page":"e011869","DOI":"10.1161\/CIRCEP.123.011869","article-title":"Interleukin-1 blockade in Cardiac sarcoidosis: a pilot study.","volume":"16","author":"Kron","year":"2023","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"6058","DOI":"10.15829\/1560-4071-2025-6058","article-title":"Inflammasome \u2014 a new look at the therapy of cardiovascular diseases. Part II.","volume":"30","author":"Rubinstein","year":"2025","journal-title":"Russian J Cardiol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1056\/NEJM196010202631603","article-title":"Sarcoid arthritis with a response to colchicine: report of two cases.","volume":"263","author":"Kaplan","year":"1960","journal-title":"N Engl J Med"},{"key":"B80","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1056\/NEJM196304042681405","article-title":"Further experience with colchicine in the treatment of sarcoid arthritis.","volume":"268","author":"Kaplan","year":"1963","journal-title":"N Engl J Med"},{"key":"B81","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1111\/jocs.15783","article-title":"Long-term survival after heart transplantation for cardiac sarcoidosis.","volume":"36","author":"McGoldrick","year":"2021","journal-title":"J Card Surg"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.healun.2022.07.018","article-title":"The International thoracic organ transplant registry of the international society for heart and lung transplantation: thirty-ninth adult heart transplantation report-2022; focus on transplant for restrictive heart disease.","volume":"41","author":"Hsich","year":"2022","journal-title":"J Heart Lung Transplant"},{"key":"B83","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/ajt.14128","article-title":"OPTN\/SRTR 2015 annual data report: heart.","volume":"17","author":"Colvin","year":"2017","journal-title":"Am J Transplant"},{"key":"B84","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.amjcard.2022.01.025","article-title":"Pericardial Involvement in sarcoidosis.","volume":"170","author":"Mahalwar","year":"2022","journal-title":"Am J Cardiol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/j.healun.2025.04.014","article-title":"The international thoracic organ transplant registry of the international society for heart and lung transplantation: 2025 annual report of heart and lung transplantation.","volume":"44","author":"Singh","year":"2025","journal-title":"J Heart Lung Transplantation."},{"key":"B86","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.healun.2021.08.012","article-title":"Heart transplantation outcomes in cardiac sarcoidosis.","volume":"41","author":"Jackson","year":"2022","journal-title":"J Heart Lung Transplant"},{"key":"B87","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ijcard.2019.12.066","article-title":"Sarcoidosis diagnosed on granulomas in the explanted heart after transplantation: results of a French nationwide study.","volume":"307","author":"Chazal","year":"2020","journal-title":"Int J Cardiol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/j.healun.2024.05.010","article-title":"International society for heart and lung transplantation guidelines for the evaluation and care of cardiac transplant candidates-2024.","volume":"43","author":"Peled","year":"2024","journal-title":"J Heart Lung Transplant"},{"key":"B89","doi-asserted-by":"crossref","DOI":"10.5772\/intechopen.72019","volume-title":"Side Effects of Glucocorticoids.","author":"Alan","year":"2018"},{"key":"B90","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00392-021-01920-0","article-title":"Short- and long-term outcomes after heart transplantation in cardiac sarcoidosis and giant-cell myocarditis: a systematic review and meta-analysis.","volume":"111","author":"Bobbio","year":"2022","journal-title":"Clin Res Cardiol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1002\/ehf2.13789","article-title":"Outcomes after heart transplantation in patients with cardiac sarcoidosis.","volume":"9","author":"Asleh","year":"2022","journal-title":"ESC Heart Fail"},{"key":"B92","doi-asserted-by":"publisher","first-page":"S261","DOI":"10.1016\/j.healun.2020.01.567","article-title":"Management of cardiac sarcoidosis post heart transplantation: survey of transplant centers.","volume":"39","author":"Pandya","year":"2020","journal-title":"J Heart Lung Transplant."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1378\/chest.07-2784","article-title":"Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing.","volume":"133","author":"Mehta","year":"2008","journal-title":"Chest"},{"key":"B94","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.3390\/jcm9082363","article-title":"Clinical presentations, pathogenesis, and therapy of sarcoidosis: state of the art.","volume":"9","author":"Polverino","year":"2020","journal-title":"J Clin Med"},{"key":"B95","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1016\/s2665-9913(20)30065-5","article-title":"Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial.","volume":"2","author":"Kl\u00fcck","year":"2020","journal-title":"Lancet Rheumatol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1723644\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T06:43:55Z","timestamp":1773125035000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1723644\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":95,"alternative-id":["10.3389\/fmed.2026.1723644"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1723644","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"article-number":"1723644"}}